Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Red Yeast Rice and Low-dose Atorvastatin vs Standard Atorvastatin in Mild ASCVD
NCT02726555Phase 3Recruiting
- Sponsor
- Wenzhou Medical University
- Start
- Nov 2015
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Xuezhikang in atherosclerotic cardiovascular disease (ASCVD) and dyslipidemia (2 arms), sponsored by Wenzhou Medical University. Primary endpoint: Low-density lipoprotein cholesterol at 24 weeks. Started Nov 2015; status: recruiting.
02
Drugs
Xuezhikang
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)dyslipidemia
Beyond the preview
Go deeper on NCT02726555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02726555.